Urine evaluation recommended for recurrent stone formers

The UroRisk Diagnostic Profile from Mission Pharmacal is available forurine metabolic evaluation of renal stone disease. This test is recommendedfor initial and recurrent stone formers and those who do not test positivefor urinary tract infection. UroRisk is a semi-comprehensive evaluationthat measures nine risk factors for stone formation, the company says. Testresults are reported on an easy-to-read graphic display.

Related Videos

Related Content

Advertisement

April 21st 2025

Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan

Hannah Clarke

Treatment with nadofaragene led to a complete response rate of 75% at 3 months.

April 21st 2025

Introducing Pearls & Perspectives, with Amy Pearlman, MD!

Amy M. Pearlman, MD

Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.

April 18th 2025

U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery Centers

Michigan Institute of Urology

Ambulatory surgery centers were evaluated based entirely on objective, risk-adjusted measures of their patients’ outcomes.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff

Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.

Related Content

Advertisement

April 21st 2025

Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan

Hannah Clarke

Treatment with nadofaragene led to a complete response rate of 75% at 3 months.

April 21st 2025

Introducing Pearls & Perspectives, with Amy Pearlman, MD!

Amy M. Pearlman, MD

Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.

April 18th 2025

U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery Centers

Michigan Institute of Urology

Ambulatory surgery centers were evaluated based entirely on objective, risk-adjusted measures of their patients’ outcomes.

March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff

Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.